CDET

Introduction
• The first USFDA-approved drug that contains an API (Cannabidiol (CBD)) derived from
marijuana to treat rare, severe forms of seizures (Office of the Commissioner, 2018).

Image 1(Parrett, 2019)

 Indication
• The product is used as adjuvantive therapy (with clobazam) of seizures
associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome
(DS), for patients 2 years of age and older. Also for seizures associated
with tuberous sclerosis complex (TSC) for patients 2 years of age and
older as adjuvantive therapy (EMA,2019).
 Mode of action
• The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant
effect in humans are unknown.
• Cannabidiol does not appear to exert its anticonvulsant effects
through interaction with cannabinoid receptors.
Interesting factors
Interesting factors
Interesting factors
Interesting factors
Interesting factors
Interesting factors
 REFERENCES
• Office of the Commissioner. (2018) FDA Approves First Drug Comprised of an Active Ingredient Derived from
Marijuana to Treat Rare, Severe Forms of Epilepsy | FDA. Available at: https://www.fda.gov/news-events/press-
announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
(Accessed: 25 October 2023).
• McClurg, L. (2018, August 3). Mom, desperate to help her son, drove the first cannabis pharmaceutical to market.
KQED. https://www.kqed.org/futureofyou/443383/meet-sam-the-berkeley-kid-who-inspired-first-marijuana-
based-drug (Accessed: 25 October 2023).

• Sinclair, S. (2021, March 15). “it’s time to celebrate her legacy”: Charlotte Figi to be remembered with tribute
concert. Cannabis Health News. https://cannabishealthnews.co.uk/2021/03/03/its-time-to-celebrate-her-legacy-
charlotte-figi-to-be-remembered-with-tribute-concert/ (Accessed: 25 October 2023).
• Jones, N. A. , Hill, A. J. , Smith, I. , Bevan, S. A. , Williams, C. M. , Whalley, B. J. , & Stephens, G. J. (2010).
Cannabidiol displays anti‐epileptiform and anti‐seizure properties in vitro and in vivo. The Journal of
Pharmacology and Experimental Therapeutics, 332, 569–577.